Cochrane · systematic review · CD008398
Oral versus intravenous fluoropyrimidines for colorectal cancer
Chionh, F, Lau, D, Yeung, Y, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
ColorectalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 10%Low 3 · 30%Moderate 4 · 40%High 2 · 20%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Oral compared with intravenous fluoropyrimidines for colorectal cancer ‐ Patients treated with curative intent
Population: Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Disease‐free survival Oral vs intravenous fluoropyrimidines | HR 0.93 [0.87, 1] | 7 studies · 8903 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Overall survival Oral vs intravenous fluoropyrimidines | HR 0.92 [0.84, 1] | 7 studies · 8902 participants | High |
Grade ≥ 3 diarrhoea Oral vs intravenous fluoropyrimidines | OR 1.12 [0.99, 1.25] | 9 studies · 9551 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Grade ≥ 3 hand foot syndrome Oral vs intravenous fluoropyrimidines | OR 4.59 [2.97, 7.1] | 5 studies · 5731 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Grade ≥ 3 neutropenia/granulocytopenia Oral vs intravenous fluoropyrimidines | OR 0.14 [0.11, 0.16] | 7 studies · 8087 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Oral compared with intravenous fluoropyrimidines for colorectal cancer ‐ Patients treated with palliative intent
Population: Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Progression‐free survival Oral vs intravenous fluoropyrimidines | HR 1.06 [1.02, 1.11] | 23 studies · 9927 participants | Moderate Downgraded: risk of bias, inconsistency |
Overall survival Oral vs intravenous fluoropyrimidines | HR 1.02 [0.99, 1.05] | 29 studies · 12079 participants | High |
Grade ≥ 3 diarrhoea Oral vs intravenous fluoropyrimidines | OR 1.66 [1.5, 1.84] | 30 studies · 11997 participants | Low Downgraded: risk of bias, inconsistency |
Grade ≥ 3 hand foot syndrome Oral vs intravenous fluoropyrimidines | OR 3.92 [2.84, 5.43] | 18 studies · 6481 participants | Moderate Downgraded: risk of bias, inconsistency |
Grade ≥ 3 neutropenia/granulocytopenia Oral vs intravenous fluoropyrimidines | OR 0.17 [0.15, 0.18] | 29 studies · 11794 participants | Low Downgraded: risk of bias, inconsistency |